Clinical Trials
248 trialsTIMED
UNC Lineberger Comprehensive Cancer Center
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Sound Pharmaceuticals, Incorporated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
EDDIS-a1
Petrov, Andrey
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Pfizer
A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine
University of Arkansas
Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer
Roswell Park Cancer Institute
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
TRIDENT-1
Turning Point Therapeutics, Inc.
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics, Inc.
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
CHEMOVES
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
PANDA-VAC
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
LIBRETTO-001
Eli Lilly and Company
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
RAMPART
Montefiore Medical Center
A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery
Montefiore Medical Center
GALENOS 2
Fondazione del Piemonte per l'Oncologia
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
Abramson Cancer Center at Penn Medicine
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
ALTAKRA-1405
Centre Oscar Lambret
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PNeoVCA
Mayo Clinic
AcceleRET-Lung
Hoffmann-La Roche
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Sichuan Enray Pharmaceutical Sciences Company
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Pfizer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
GUARDIAN-101
Clasp Therapeutics, Inc.
VISTA
Baylor College of Medicine
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.
EMITT-1
Grey Wolf Therapeutics
TAGNOT
Kidney Cancer Research Bureau
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Yoga Program for Improving the Quality of Life in Couples Coping With Cancer
M.D. Anderson Cancer Center